Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

3D heart mapping may unlock secrets of persistent AF treatment

NCT ID NCT04229160

Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study uses a noninvasive 3D mapping system to look at the heart's electrical activity in 50 people with persistent atrial fibrillation (AF) lasting over 6 months. Researchers want to see how the heart changes after a standard ablation procedure and what factors might predict success. The goal is to better understand why AF comes back and improve future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict who will benefit from atrial fibrillation ablation and guide more personalized treatment strategies.
What could go wrong
This is an observational study with only 50 participants, so results may not apply to everyone. It is not testing a new treatment, so direct patient benefits are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2020

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with documented persistent Atrial Fibrillation lasting longer than 6 months documented by 24h holter monitoring 2. Age between 18 and 75 years 3. Efficient oral anticoagulation during at least 1 month before the procedure 4. Social security affiliation 5. Feasible patient follow-up 6. Patient willing to comply with study requirements and give informed consent to participate in this clinical study 7. Indication for Pulmonary Vein isolation Exclusion Criteria: 1. Previous atrial fibrillation ablation 2. Previous left atrial ablation or surgery 3. Atrial fibrillation without spontaneous RR interval \> 1000ms and with LVEF \< 35% (measured by TTE) 4. Presence of a mechanical mitral valve 5. Current intracardiac thrombus 6. Any condition contraindicating chronic anticoagulation 7. Uncontrolled hyperthyroidism 8. Anteroposterior LA diameter \> 55 mm measured by TTE 9. Body mass index ≥ 40 kg/m2

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation, persistent are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation, persistent

Contacts and locations

Locations

  • Caen University Hospital

    Caen, France

  • Dieppe Hospital

    Dieppe, France

  • Groupe Hospitalier du Havre

    Le Havre, France

  • Rouen University Hospital

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.